Islin, Julie Munkboel, Cecilie Hurup and Styrishave, Bjarne 2018. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Toxicology in Vitro, Vol. 47, p. 63.
Xue, Weiwei Yang, Fengyuan Wang, Panpan Zheng, Guoxun Chen, Yuzong Yao, Xiaojun and Zhu, Feng 2018. What Contributes to Serotonin–Norepinephrine Reuptake Inhibitors’ Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. ACS Chemical Neuroscience,
Yazici, Kemal Utku and Percinel Yazici, Ipek 2018. Visual hallucination induced by duloxetine use: a male case diagnosed with generalized anxiety disorder. Psychiatry and Clinical Psychopharmacology, p. 1.
Mosca, Daniel Zhang, Min Prieto, Rita and Boucher, Matthieu 2017. Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline. Journal of Clinical Psychopharmacology, Vol. 37, Issue. 2, p. 182.
Akbar, Mohammed Egli, Mark Cho, Young-Eun Song, Byoung-Joon and Noronha, Antonio 2017. Medications for alcohol use disorders: An overview. Pharmacology & Therapeutics,
Keyloun, Katelyn R. Hansen, Ryan N. Hepp, Zsolt Gillard, Patrick Thase, Michael E. and Devine, Emily Beth 2017. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs, Vol. 31, Issue. 5, p. 421.
Sun, Lu Fang, Liang Lian, Bin Xia, Jin-Jun Zhou, Chan-juan Wang, Ling Mao, Qiang Wang, Xin-Fa Gong, Xue Liang, Zi-Hong Bai, Shun-Jie Liao, Li Wu, Yu and Xie, Peng 2017. Biochemical effects of venlafaxine on astrocytes as revealed by 1H NMR-based metabolic profiling. Molecular BioSystems, Vol. 13, Issue. 2, p. 338.
Xue, Rui Li, Ying He, Xin-Hua Jin, Zeng-Liang Fan, Shi-Yong Zhang, Ting-Ting Li, Nuo-Min Yuan, Li Zheng, Ai-Ping Zhong, Bo-Hua Li, Yun-Feng and Zhang, You-Zhi 2017. Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors. Journal of Psychopharmacology, Vol. 31, Issue. 3, p. 377.
Martin, Sarah L. Power, Andrea Boyle, Yvonne Anderson, Ian M. Silverdale, Monty A. and Jones, Anthony K. P. 2017. 5-HT modulation of pain perception in humans. Psychopharmacology, Vol. 234, Issue. 19, p. 2929.
Dubey, Sunil K Anand, Amit and Saha, Ranendra N 2017. Enantioselective disposition of venlafaxine and its metabolite o-desmethylvenlafaxine in rats. International Journal of Pharmacokinetics, Vol. 2, Issue. 1, p. 39.
Liebe, Thomas Li, Shijia Lord, Anton Colic, Lejla Krause, Anna Linda Batra, Anil Kretzschmar, Moritz A Sweeney-Reed, Catherine M Behnisch, Gusalija Schott, Björn H and Walter, Martin 2017. Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, Vol. 20, Issue. 11, p. 909.
Nahman-Averbuch, Hadas Nir, Rony-Reuven Sprecher, Elliot and Yarnitsky, David 2016. Psychological Factors and Conditioned Pain Modulation. The Clinical Journal of Pain, Vol. 32, Issue. 6, p. 541.
Thorkelson, Gregory Bielefeldt, Klaus and Szigethy, Eva 2016. Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. Inflammatory Bowel Diseases, Vol. 22, Issue. 6, p. 1509.
David, D.J. and Gourion, D. 2016. Antidépresseurs et tolérance : déterminants et prise en charge des principaux effets indésirables. L'Encéphale, Vol. 42, Issue. 6, p. 553.
Zimmerman, Collin Atherton, Pamela J. Pachman, Deirdre Seisler, Drew Wagner-Johnston, Nina Dakhil, Shaker Lafky, Jacqueline M. Qin, Rui Grothey, Axel and Loprinzi, Charles L. 2016. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Supportive Care in Cancer, Vol. 24, Issue. 3, p. 1071.
Shah, Brijesh Khunt, Dignesh Bhatt, Himanshu Misra, Manju and Padh, Harish 2016. Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: Risk assessment and QbD based optimization. Journal of Drug Delivery Science and Technology, Vol. 33, p. 37.
Doroudgar, S Perry, PJ Lackey, GD Veselova, NG Chuang, HM and Albertson, TE 2016. An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System. Human & Experimental Toxicology, Vol. 35, Issue. 7, p. 767.
Jiang, Hai-yin Xu, Lian-lian Li, Yu-cuan Deng, Min Peng, Chun-ting and Ruan, Bing 2016. Antidepressant use during pregnancy and risk of postpartum hemorrhage: A systematic review and meta-analysis. Journal of Psychiatric Research, Vol. 83, p. 160.
Bayas, Antonios Schuh, Katrin Baier, Monika Vormfelde, Stefan Viktor Koppai-Reiner, Joachim Strauss, Erik Haerting, Beatrix Wiehler, Stephan Boehringer, Johannes Laumen, Peter Christopher, Angelika Pfeiffer, Uwe Hofmann, Werner Horn, Rolf Lauter, Thorsten Polzer, Udo Halbgewachs, Frank Siever, Arno Honig, Holger Mahler, Andreas Kuhlgert, Karsten Weber, Martin Bischof, Felix Martin Hoffmann, Olaf Merkelbach, Stefan Ralf Kessler, Kirn Wenzelburger, Roland Mayer, Geert and Strittmatter, Matthias 2016. Combination treatment of fingolimod with antidepressants in relapsing–remitting multiple sclerosis patients with depression: a multicentre, open-label study – REGAIN. Therapeutic Advances in Neurological Disorders, Vol. 9, Issue. 5, p. 378.
Bielefeldt, Klaus 2016. Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. Digestive Diseases and Sciences, Vol. 61, Issue. 9, p. 2655.
Mowla, Arash Boostani, Sanaz and Dastgheib, Seyed Ali 2016. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, Vol. 36, Issue. 6, p. 720.
Camacho, Álvaro McClelland, Robyn L. Delaney, Joseph A. Allison, Matthew A. Psaty, Bruce M. Rifkin, Dena E. Rapp, Stephen R. Szklo, Moyses Stein, Murray B. and Criqui, Michael H. 2016. Antidepressant Use and Subclinical Measures of Atherosclerosis. Journal of Clinical Psychopharmacology, Vol. 36, Issue. 4, p. 340.
Zhang, Yingli Huang, Guoping Yang, Shichang Liang, Wei Zhang, Lei and Wang, Changhong 2016. Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials. Asia-Pacific Psychiatry, Vol. 8, Issue. 3, p. 215.
Khan, Junad Alghamdi, Hamed Anwer, Muhammad Moin Eliav, Eli and Ziccardi, Vincent 2016. Role of Collagen Conduit With Duloxetine and/or Pregabalin in the Management of Partial Peripheral Nerve Injury. Journal of Oral and Maxillofacial Surgery, Vol. 74, Issue. 6, p. 1120.
Litwack, Kim 2015. Pain Management in Military Trauma. Critical Care Nursing Clinics of North America, Vol. 27, Issue. 2, p. 235.
Thase, Michael E. Fayyad, Rana Cheng, Ru-fong J. Guico-Pabia, Christine J. Sporn, Jonathan Boucher, Matthieu and Tourian, Karen A. 2015. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Current Medical Research and Opinion, Vol. 31, Issue. 4, p. 809.
Brouwer, Brigitte A. de Greef, Bianca T. A. Hoeijmakers, Janneke G. J. Geerts, Margot van Kleef, Maarten Merkies, Ingemar S. J. and Faber, Catharina G. 2015. Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects. Drugs & Aging, Vol. 32, Issue. 8, p. 611.
Chen, Laishun Greenberg, William M. Gommoll, Carl O’Connor, Joann Zukin, Stephen R. Periclou, Antonia and Ghahramani, Parviz 2015. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. Clinical Therapeutics, Vol. 37, Issue. 9, p. 2059.
Korte, S. Mechiel Prins, Jolanda Krajnc, Anne M. Hendriksen, Hendrikus Oosting, Ronald S. Westphal, Koen G. Korte-Bouws, Gerdien A.H. and Olivier, Berend 2015. The many different faces of major depression: It is time for personalized medicine. European Journal of Pharmacology, Vol. 753, p. 88.
Spindelegger, C. J. Papageorgiou, K. Grohmann, R. Engel, R. Greil, W. Konstantinidis, A. Agelink, M. W. Bleich, S. Ruether, E. Toto, S. and Kasper, S. 2015. Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010. International Journal of Neuropsychopharmacology, Vol. 18, Issue. 4, p. pyu080.
Jiang, Hai-Yin Chen, Hua-Zhong Hu, Xin-Jun Yu, Zheng-He Yang, Wei Deng, Min Zhang, Yong-Hua and Ruan, Bing 2015. Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, Vol. 13, Issue. 1, p. 42.
Mold, James W. and Holtzclaw, Barbara J. 2015. Selective Serotonin Reuptake Inhibitors and Night Sweats in a Primary Care Population. Drugs - Real World Outcomes, Vol. 2, Issue. 1, p. 29.
Vel’tishchev, D. Yu. 2015. Efficacy of Venlafaxine (Velaxin) in the Treatment of Depression: Results of Recent Trials. Neuroscience and Behavioral Physiology, Vol. 45, Issue. 5, p. 576.
Zhou, Yan Zhang, Guoqiang Rao, Zhi Yang, Yang Zhou, Qian Qin, Hongyan Wei, Yuhui and Wu, Xin’an 2015. Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. Archives of Pharmacal Research, Vol. 38, Issue. 7, p. 1325.
Correll, Christoph U. Detraux, Johan De Lepeleire, Jan and De Hert, Marc 2015. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, Vol. 14, Issue. 2, p. 119.
Paudel, Suresh Cao, Yongkai Guo, Shuohan An, Byeongkwan Kim, Kyeong-Man and Cheon, Seung Hoon 2015. Design and synthesis of 4-benzylpiperidine carboxamides as dual serotonin and norepinephrine reuptake inhibitors. Bioorganic & Medicinal Chemistry, Vol. 23, Issue. 19, p. 6418.
Saulino, Michael 2014. Spinal Cord Injury Pain. Physical Medicine and Rehabilitation Clinics of North America, Vol. 25, Issue. 2, p. 397.
Biondi, David M. Xiang, Jim Etropolski, Mila and Moskovitz, Bruce 2014. Evaluation of Blood Pressure and Heart Rate in Patients with Hypertension Who Received Tapentadol Extended Release for Chronic Pain: A Post Hoc, Pooled Data Analysis. Clinical Drug Investigation, Vol. 34, Issue. 8, p. 565.
Lee, Mi-gyung Oh, Daeyoung Choi, Mi-Ran Chai, Young-Gyu Kim, Seok-Hyeon Oh, Dong-Hoon and Choi, Joonho 2014. NCAM140 and pCREB Expression after Tianeptine Treatment of SH-SY5Y Cells. Psychiatry Investigation, Vol. 11, Issue. 3, p. 313.
Zhang, Xin Kang, Deying Zhang, Lan and Peng, Le 2014. Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. Aging & Mental Health, Vol. 18, Issue. 8, p. 941.
Mago, Rajnish Mahajan, Rajeev and Thase, Michael E 2014. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Review of Clinical Pharmacology, Vol. 7, Issue. 2, p. 137.
Sassarini, Jenifer Krishnadas, Rajeev Cavanagh, Jonathan Nicol, Alice Pimlott, Sally L. Ferrell, William and Lumsden, Mary Ann 2014. Venlafaxine alters microvascular perfusion, [123I]-beta-CIT binding and BDI scores in flushing postmenopausal women. Maturitas, Vol. 77, Issue. 3, p. 267.
Kale, Pravin Popatrao Addepalli, Veeranjaneyulu Sarkar, Amrita Patel, Sonam and Savai, Jay 2014. The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity. Experimental Neurobiology, Vol. 23, Issue. 3, p. 224.
Gommoll, Carl P. Greenberg, William M. and Chen, Changzheng 2014. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder. Journal of Drug Assessment, Vol. 3, Issue. 1, p. 10.
Mittal, Deepti Ali, Asgar Md, Shadab Baboota, Sanjula Sahni, Jasjeet K. and Ali, Javed 2014. Insights into direct nose to brain delivery: current status and future perspective. Drug Delivery, Vol. 21, Issue. 2, p. 75.
Sambunaris, Angelo Bose, Anjana Gommoll, Carl P. Chen, Changzheng Greenberg, William M. and Sheehan, David V. 2014. A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology, Vol. 34, Issue. 1, p. 47.
Kale, Pravin Popatrao and Addepalli, Veeranjaneyulu 2014. Augmentation of antidepressant effects of duloxetine and bupropion by caffeine in mice. Pharmacology Biochemistry and Behavior, Vol. 124, p. 238.
Thombs, Brett D Ziegelstein, Roy C Roseman, Michelle Kloda, Lorie A and Ioannidis, John PA 2014. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine, Vol. 12, Issue. 1,
Pilgrim, Jennifer L. Gerostamoulos, Dimitri and Drummer, Olaf H. 2014. The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009–2012). Forensic Science International, Vol. 234, p. 165.
Saraceni, Megan M. Venci, Jineane V. and Gandhi, Mona A. 2014. Levomilnacipran (Fetzima). Journal of Pharmacy Practice, Vol. 27, Issue. 4, p. 389.
Michl, Johanna Scharinger, Christian Zauner, Miriam Kasper, Siegfried Freissmuth, Michael Sitte, Harald H. Ecker, Gerhard F. and Pezawas, Lukas 2014. A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. European Neuropsychopharmacology, Vol. 24, Issue. 9, p. 1463.
Karger, Stefan Wiesner, Tobias Kersting, Anette Braun, Miriam Ebert, Thomas Wurst, Ulrike Kratzsch, Juergen Stumvoll, Michael and Fasshauer, Mathias 2014. Increased Chromogranin A and Carcinoid Syndrome-Like Symptoms in a Patient Treated with Duloxetine. Endocrine Practice, Vol. 20, Issue. 11, p. e215.
Yuen, Eunice Y. Qin, Luye Wei, Jing Liu, Wenhua Liu, Aiyi and Yan, Zhen 2014. Synergistic Regulation of Glutamatergic Transmission by Serotonin and Norepinephrine Reuptake Inhibitors in Prefrontal Cortical Neurons. Journal of Biological Chemistry, Vol. 289, Issue. 36, p. 25177.
Pereira, Anthony Conwell, Yeates Gitlin, Michael J. and Dworkin, Robert H. 2014. Suicidal ideation and behavior associated with antidepressant medications: Implications for the treatment of chronic pain. Pain, Vol. 155, Issue. 12, p. 2471.
Haque, Shadabul Md, Shadab Sahni, Jasjeet Kaur Ali, Javed and Baboota, Sanjula 2014. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. Journal of Psychiatric Research, Vol. 48, Issue. 1, p. 1.
Humpston, Clara S Wood, Christian M and Robinson, Emma SJ 2013. Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task. Journal of Psychopharmacology, Vol. 27, Issue. 2, p. 213.
Bradley, Andrew J and Lenox-Smith, Alan J 2013. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. Journal of Psychopharmacology, Vol. 27, Issue. 8, p. 740.
Dutta, Lalit Ahmad, Syed Imran Mukherjee, Subhra Kanti Mishra, Sanjeev Khuroo, Arshad and Monif, Tausif 2013. Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite,O-desmethylvenlafaxine, in human plasma. Biomedical Chromatography, Vol. 27, Issue. 5, p. 622.
Fallon, M.T. 2013. Neuropathic pain in cancer. British Journal of Anaesthesia, Vol. 111, Issue. 1, p. 105.
Myers, Alyson K. and Trivedi, Madhukar H. 2013. The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability. Psychopharm Review, Vol. 48, Issue. 1, p. 1.
Tsutsui-Kimura, Iku Ohmura, Yu Izumi, Takeshi Kumamoto, Haruko Yamaguchi, Taku Yoshida, Takayuki and Yoshioka, Mitsuhiro 2013. Milnacipran enhances the control of impulsive action by activating D1-like receptors in the infralimbic cortex. Psychopharmacology, Vol. 225, Issue. 2, p. 495.
Auclair, A.L. Martel, J.C. Assié, M.B. Bardin, L. Heusler, P. Cussac, D. Marien, M. Newman-Tancredi, A. O'Connor, J.A. and Depoortère, R. 2013. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety. Neuropharmacology, Vol. 70, p. 338.
Satheesh Kumar, R. Challa, Siva R. Lal Babu, G. Rekha, K. Renuka Devi, V. Srinu, S. Challa, Venkatesh R. and Narendra Babu, S. 2013. Influence of Duloxetine on the in-vivo pharmacokinetics of Metoprolol in rat model. Journal of Pharmacy Research, Vol. 7, Issue. 4, p. 362.
Naegeli, Kale J. O’Connor, Joann A. Banerjee, Pradeep and Morilak, David A. 2013. Effects of milnacipran on cognitive flexibility following chronic stress in rats. European Journal of Pharmacology, Vol. 703, Issue. 1-3, p. 62.
Diaper, Alison Rich, Ann S. Wilson, Sue J. Craig, Kevin Dourish, Colin T. Dawson, Gerry R. Nutt, David J. and Bailey, Jayne E. 2013. Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Human Psychopharmacology: Clinical and Experimental, Vol. 28, Issue. 6, p. 562.
Thombs, Brett D. Roseman, Michelle Coyne, James C. de Jonge, Peter Delisle, Vanessa C. Arthurs, Erin Levis, Brooke Ziegelstein, Roy C. and Laks, Jerson 2013. Does Evidence Support the American Heart Association's Recommendation to Screen Patients for Depression in Cardiovascular Care? An Updated Systematic Review. PLoS ONE, Vol. 8, Issue. 1, p. e52654.
Xue, Rui Jin, Zeng-Liang Chen, Hong-Xia Yuan, Li He, Xin-Hua Zhang, Yan-Ping Meng, Yong-Gang Xu, Jiang-Ping Zheng, Jian-Quan Zhong, Bo-Hua Li, Yun-Feng and Zhang, You-Zhi 2013. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. European Neuropsychopharmacology, Vol. 23, Issue. 7, p. 728.
Fornaro, Michele Rocchi, Giulio Escelsior, Andrea Contini, Paola and Martino, Matteo 2013. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. Journal of Affective Disorders, Vol. 145, Issue. 3, p. 300.
Whiskey, Eromona and Taylor, David 2013. A review of the adverse effects and safety of noradrenergic antidepressants. Journal of Psychopharmacology, Vol. 27, Issue. 8, p. 732.
Mago, Rajnish Forero, Giovanna Greenberg, William M. Gommoll, Carl and Chen, Changzheng 2013. Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study. Clinical Drug Investigation, Vol. 33, Issue. 10, p. 761.
Dreyfus, Nicolas Myers, Jason K. Badescu, Valentina O. de Frutos, Oscar de la Puente, Maria Luz Ding, Chunjin Filla, Sandra A. Fynboe, Karsten Gernert, Douglas L. Heinz, Beverly A. Hemrick-Luecke, Susan K. Johnson, Kirk W. Johnson, Michael P. López, Pilar Love, Patrick L. Martin, Laura J. Masquelin, Thierry McCoy, Michael J. Mendiola, Javier Morrow, Denise Muhlhauser, Mark Pascual, Gustavo Perun, Thomas J. Pfeifer, Lance A. Phebus, Lee A. Richards, Simon J. Rincón, Juan Antonio Seest, Eric P. Shah, Jikesh Shaojuan, Jia Simmons, Rosa Maria A. Stephenson, Gregory A. Tromiczak, Eric G. Thompson, Linda K. Walter, Magnus W. Weber, Wayne W. Zarrinmayeh, Hamideh Thomas, Craig E. Joshi, Elizabeth Iyengar, Smriti and Johansson, Anette M. 2013. Discovery of a Potent, Dual Serotonin and Norepinephrine Reuptake Inhibitor. ACS Medicinal Chemistry Letters, Vol. 4, Issue. 6, p. 560.
Fulda, Stephany Kloiber, Stefan Dose, Tatjana Lucae, Susanne Holsboer, Florian Schaaf, Ludwig and Hennings, Johannes 2013. Mirtazapine Provokes Periodic Leg Movements during Sleep in Young Healthy Men. Sleep, Vol. 36, Issue. 5, p. 661.
Raddad, E Melhem, M R Sloan-Lancaster, J S Miller, J W Van Wart, S A and Rubino, C M 2013. Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor. CPT: Pharmacometrics & Systems Pharmacology, Vol. 2, Issue. 8, p. e66.
Citrome, L. 2013. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice, Vol. 67, Issue. 11, p. 1089.
Pund, Swati Rasve, Ganesh and Borade, Ganesh 2013. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. European Journal of Pharmaceutical Sciences, Vol. 48, Issue. 1-2, p. 195.
Malfait, Anne-Marie and Schnitzer, Thomas J. 2013. Towards a mechanism-based approach to pain management in osteoarthritis. Nature Reviews Rheumatology, Vol. 9, Issue. 11, p. 654.
Bet, Pierre M. Hugtenburg, Jacqueline G. Penninx, Brenda W.J.H. and Hoogendijk, Witte J.G. 2013. Side effects of antidepressants during long-term use in a naturalistic setting. European Neuropsychopharmacology, Vol. 23, Issue. 11, p. 1443.
Mika, Joanna Zychowska, Magdalena Makuch, Wioletta Rojewska, Ewelina and Przewlocka, Barbara 2013. Neuronal and immunological basis of action of antidepressants in chronic pain – clinical and experimental studies. Pharmacological Reports, Vol. 65, Issue. 6, p. 1611.
Nagayasu, Kazuki Kitaichi, Maiko Nishitani, Naoya Asaoka, Nozomi Shirakawa, Hisashi Nakagawa, Takayuki and Kaneko, Shuji 2013. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release. The International Journal of Neuropsychopharmacology, Vol. 16, Issue. 10, p. 2295.
Schlaepfer, Thomas E Ågren, Hans Monteleone, Palmiero Gasto, Cristobal Pitchot, William Rouillon, Frederick Nutt, David J and Kasper, Siegfried 2012. The hidden third: improving outcome in treatment-resistant depression. Journal of Psychopharmacology, Vol. 26, Issue. 5, p. 587.
Zomkowski, Andréa D.E. Engel, Daiane Cunha, Mauricio P. Gabilan, Nelson H. and Rodrigues, Ana Lúcia S. 2012. The role of the NMDA receptors and l-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test. Pharmacology Biochemistry and Behavior, Vol. 103, Issue. 2, p. 408.
Hung, Ching-I Liu, Chia-Yih Yang, Ching-Hui and Wang, Shuu-Jiun 2012. Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder. Psychiatry and Clinical Neurosciences, Vol. 66, Issue. 1, p. 8.
Payandemehr, Borna Bahremand, Arash Rahimian, Reza Ziai, Pouya Amouzegar, Afsaneh Sharifzadeh, Mohammad and Dehpour, Ahmad Reza 2012. 5-HT3 receptor mediates the dose-dependent effects of citalopram on pentylenetetrazole-induced clonic seizure in mice: Involvement of nitric oxide. Epilepsy Research, Vol. 101, Issue. 3, p. 217.
Graves, Steven M. Rafeyan, Roueen Watts, Jeffrey and Napier, T. Celeste 2012. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: Evidence from the bench and the bedside. Pharmacology & Therapeutics, Vol. 136, Issue. 3, p. 343.
Raskin, Joel George, Thomas Granger, Renee E. Hussain, Nadia Zhao, George Weizhong and Marangell, Lauren B. 2012. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: Outcomes following randomized switch to either duloxetine or escitalopram. Journal of Psychiatric Research, Vol. 46, Issue. 5, p. 667.
Hedge, Matthew W. 2012. Miscellaneous Central Nervous System Intoxicants. Critical Care Clinics, Vol. 28, Issue. 4, p. 587.
Cates, Marshall E Wensel, Terri M Waldrop, Bruce A and Iranikhah, Maryam M 2012. Antidepressant Pharmacology: Introduction for the Pharmacy Technician. Journal of Pharmacy Technology, Vol. 28, Issue. 1, p. 26.
Baek, Jong-Suep Lim, Ji-Ho So, Jae-Woo Kim, Jae-Il Lee, Tae-Wan Hwang, Sung-Joo Shin, Sang-Chul Kim, Soo-Jin and Cho, Cheong-Weon 2012. The feasibility study of transdermal drug delivery systems for antidepressants possessing hydrophilicity or hydrophobicity. Journal of Pharmaceutical Investigation, Vol. 42, Issue. 3, p. 109.
Palmsten, Kristin Setoguchi, Soko Margulis, Andrea V. Patrick, Amanda R. and Hernández-Díaz, Sonia 2012. Elevated Risk of Preeclampsia in Pregnant Women With Depression: Depression or Antidepressants?. American Journal of Epidemiology, Vol. 175, Issue. 10, p. 988.
Xu, Bo Descalzi, Giannina Ye, Hai-Rong Zhuo, Min and Wang, Ying-Wei 2012. Translational Investigation and Treatment of Neuropathic Pain. Molecular Pain, Vol. 8, p. 1744-8069-8-15.
Ozdemir, Ercan Gursoy, Sinan and Bagcivan, Ihsan 2012. The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. The Journal of Physiological Sciences, Vol. 62, Issue. 4, p. 317.
Rojas-Fernandez, Carlos and Mikhail, Mina 2012. Contemporary Concepts in the Pharmacotherapy of Depression in Older People. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, Vol. 145, Issue. 3, p. 128.
Haque, Shadabul Md, Shadab Fazil, Mohammad Kumar, Manish Sahni, Jasjeet Kaur Ali, Javed and Baboota, Sanjula 2012. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. Carbohydrate Polymers, Vol. 89, Issue. 1, p. 72.
Li, Chen Li, Bin-Feng Chen, Jian-Ge Sun, Tao and Chen, Zhenming 2012. A Practical Kilogram-Scale Process to a Milnacipran Analogue, N,N-Diallyl (1R, 2R)-2-(Aminomethyl)-1-(2-thienyl)cyclopropanecarboxamide. Organic Process Research & Development, Vol. 16, Issue. 12, p. 2021.
Ferguson, James M. Tourian, Karen A. and Rosas, Gregory R. 2012. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectrums, Vol. 17, Issue. 03, p. 121.
Xue, Fei Strombom, Indiana Turnbull, Bruce Zhu, Shao and Seeger, John 2012. Treatment With Duloxetine in Adults and the Incidence of Cardiovascular Events. Journal of Clinical Psychopharmacology, Vol. 32, Issue. 1, p. 23.
Baastrup, Cathrine and Finnerup, Nanna Brix 2012. Pain in spinal cord injury. Pain Management, Vol. 2, Issue. 1, p. 87.
Yang, Ya-Hsu Lin, Jen-Kou Chen, Wei-Shone Lin, Tzu-Chen Yang, Shung-Haur Jiang, Jeng-Kai Chang, Shih-Ching Lan, Yuan-Tzu Lin, Chun-Chi Yen, Chueh-Chuan Tzeng, Cheng-Hwai Wang, Wei-Shu Chiang, Huey-Ling Teng, Chung-Jen and Teng, Hao-Wei 2012. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Supportive Care in Cancer, Vol. 20, Issue. 7, p. 1491.
Ipser, Jonathan C. and Stein, Dan J. 2012. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). The International Journal of Neuropsychopharmacology, Vol. 15, Issue. 06, p. 825.
Signorovitch, James Ramakrishnan, Karthik Ben-Hamadi, Rym Yu, Andrew P. Wu, Eric Q. Dworak, Heather and Erder, M. Haim 2011. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Current Medical Research and Opinion, Vol. 27, Issue. 6, p. 1089.
Del Pace, Stefano Parodi, Guido Bellandi, Benedetta Zampini, Linda Venditti, Francesco Ardito, Matilde Antoniucci, David and Gensini, Gian Franco 2011. Anxiety trait in patients with stress-induced cardiomyopathy: a case–control study. Clinical Research in Cardiology, Vol. 100, Issue. 6, p. 523.
Berrocoso, Esther Mico, Juan-Antonio Vitton, Olivier Ladure, Philippe Newman-Tancredi, Adrian Depoortère, Ronan and Bardin, Laurent 2011. Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. European Journal of Pharmacology, Vol. 655, Issue. 1-3, p. 46.
Hache, Guillaume Coudore, François Gardier, Alain M. and Guiard, Bruno P. 2011. Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs). Pharmaceuticals, Vol. 4, Issue. 12, p. 285.
Sugimoto, Koreaki 2011. The Dubious Effect of Milnacipran for the Treatment of Burning Mouth Syndrome. Clinical Neuropharmacology, Vol. 34, Issue. 4, p. 170.
Hung, Ching-I Wang, Shuu-Jiun Liu, Chia-Yih Hsu, Shih-Chieh and Yang, Ching-Hui 2011. Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder. Comprehensive Psychiatry, Vol. 52, Issue. 4, p. 370.
Kobayashi, Toru Washiyama, Kazuo Ikeda, Kazutaka and Hashimoto, Kenji 2011. Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by Different Classes of Antidepressants. PLoS ONE, Vol. 6, Issue. 12, p. e28208.
Ye, Wenyu Zhao, Yang Robinson, Rebecca L and Swindle, Ralph W 2011. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder. BMC Psychiatry, Vol. 11, Issue. 1,
Prins, Jolanda Olivier, Berend and Korte, S Mechiel 2011. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opinion on Investigational Drugs, Vol. 20, Issue. 8, p. 1107.
McDonald, Jaime Corbeil, Philippe and Pourcher, Emmanuelle 2011. Balance Control Improves Following Replacement of Paroxetine with Venlafaxine and Levodopa in a Case of Microvascular Dementia. The American Journal of Geriatric Pharmacotherapy, Vol. 9, Issue. 2, p. 133.
Schueler, Y.-B. Koesters, M. Wieseler, B. Grouven, U. Kromp, M. Kerekes, M. F. Kreis, J. Kaiser, T. Becker, T. and Weinmann, S. 2011. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatrica Scandinavica, Vol. 123, Issue. 4, p. 247.
Song, Ji-Hye Yu, Bum-Hee Lee, Dongsoo Yoon, Se Chang and Jeon, Hong Jin 2011. Uncontrolled Self-Medication with Venlafaxine in a Patient with Major Depressive Disorder. Psychiatry Investigation, Vol. 8, Issue. 1, p. 74.
Soleimani, Laili Lapidus, Kyle A.B. and Iosifescu, Dan V. 2011. Diagnosis and Treatment of Major Depressive Disorder. Neurologic Clinics, Vol. 29, Issue. 1, p. 177.
Andrews, Nick and O’Neill, Michael F 2011. It might be a big family but the pain remains—last chance saloon for selective 5-HT receptor ligands?. Current Opinion in Pharmacology, Vol. 11, Issue. 1, p. 39.
Sangkuhl, Katrin Klein, Teri E. and Altman, Russ B. 2011. PharmGKB summary. Pharmacogenetics and Genomics, Vol. 21, Issue. 11, p. 769.
Lovatt, Penny 2011. Serotonin–norepinephrine inhibitors: pharmacological profile. Nurse Prescribing, Vol. 9, Issue. 7, p. 350.
Bitter, Istvan Filipovits, Dora and Czobor, Pal 2011. Adverse reactions to duloxetine in depression. Expert Opinion on Drug Safety, Vol. 10, Issue. 6, p. 839.
Paterson, Neil E Balci, Fuat Campbell, Una Olivier, Berend E and Hanania, Taleen 2011. The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition. Journal of Psychopharmacology, Vol. 25, Issue. 10, p. 1357.
Karlsson, Louise Hiemke, Christoph Carlsson, Björn Josefsson, Martin Ahlner, Johan Bengtsson, Finn Schmitt, Ulrich and Kugelberg, Fredrik C. 2011. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology, Vol. 215, Issue. 2, p. 367.
Bochsler, Lanny Olver, James S and Norman, Trevor R 2011. Duloxetine in the acute and continuation treatment of major depressive disorder. Expert Review of Neurotherapeutics, Vol. 11, Issue. 11, p. 1525.
Launiainen, Terhi Rasanen, Ilpo Vuori, Erkki and Ojanperä, Ilkka 2011. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. International Journal of Legal Medicine, Vol. 125, Issue. 3, p. 349.
Tanaka, Yukari Kanazawa, Motoyori Fukudo, Shin and Drossman, Douglas A 2011. Biopsychosocial Model of Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, Vol. 17, Issue. 2, p. 131.
Malfroy, S. Tassin, C. Attof, R. Perdrix, J.-P. and Piriou, V. 2011. Choc cardiogénique après intoxication médicamenteuse volontaire à la venlafaxine. Annales Françaises d'Anesthésie et de Réanimation, Vol. 30, Issue. 11, p. 857.
Kitanaka, Nobue Kitanaka, Junichi Tatsuta, Tomohiro Tanaka, Koh-ichi Watabe, Kaname Nishiyama, Nobuyoshi Morita, Yoshio and Takemura, Motohiko 2010. Withdrawal from Fixed-Dose Injection of Methamphetamine Decreases Cerebral Levels of 3-Methoxy-4-hydroxyphenylglycol and Induces the Expression of Anxiety-Related Behavior in Mice. Neurochemical Research, Vol. 35, Issue. 5, p. 749.
Tsuruda, Pamela R. Yung, Joey Martin, William J. Chang, Ray Mai, Ngoc and Smith, Jacqueline A.M. 2010. Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters. Journal of Pharmacological and Toxicological Methods, Vol. 61, Issue. 2, p. 192.
Aggarwal, Ashish Khandelwal, Ashish and Jiloha, Ram C. 2010. Milnacipran-Associated Urinary Retention. Journal of Clinical Psychopharmacology, Vol. 30, Issue. 5, p. 641.
Smith, Howard S. Bracken, Donna and Smith, Joshua M. 2010. Duloxetine: A Review of its Safety and Efficacy in the Management of Fibromyalgia Syndrome. Journal of Central Nervous System Disease, Vol. 2, p. JCNSD.S4127.
Bardin, L. Gregoire, S. Aliaga, M. Malfetes, N. Vitton, O. Ladure, P. Newman-Tancredi, A. and Depoortère, R. 2010. Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neuroscience Research, Vol. 66, Issue. 2, p. 135.
Palmer, Robert H. Periclou, Antonia and Banerjee, Pradeep 2010. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. Therapeutic Advances in Musculoskeletal Disease, Vol. 2, Issue. 4, p. 201.
Hewett, Karen Gee, Michelle D Krishen, Alok Wunderlich, Hans-Peter Le Clus, Alfred Evoniuk, Gary and Modell, Jack G 2010. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of Psychopharmacology, Vol. 24, Issue. 8, p. 1209.
Frassetto, Silvana S. Alves, Isis O. Santos, Marislane M. Schmidt, Ana E. S. Lopes, Janaína J. Oliveira, Paulo A. Vinagre, Anapaula S. and Pereira, Patrícia 2010. Absence of sibutramine effect on spontaneous anxiety in rats. Arquivos Brasileiros de Endocrinologia & Metabologia, Vol. 54, Issue. 4, p. 375.
Mitsumori, Yoshitaka Nakamura, Yuji Hoshiai, Kiyotaka Nagayama, Yukitoshi Adachi-Akahane, Satomi Koizumi, Schuichi Matsumoto, Masahiko and Sugiyama, Atsushi 2010. In Vivo Canine Model Comparison of Cardiovascular Effects of Antidepressants Milnacipran and Imipramine. Cardiovascular Toxicology, Vol. 10, Issue. 4, p. 275.
Hung, Ching-I Liu, Chia-Yih Wang, Shuu-Jiun Juang, Yeong-Yuh and Yang, Ching-Hui 2010. Somatic symptoms: An important index in predicting the outcome of depression at six-month and two-year follow-up points among outpatients with major depressive disorder. Journal of Affective Disorders, Vol. 125, Issue. 1-3, p. 134.
Begré, S. Traber, M. Gerber, M. and von Känel, R. 2010. Physician speciality and pain reduction in patients with depressive symptoms under treatment with venlafaxine. European Psychiatry, Vol. 25, Issue. 8, p. 455.
Rojas-Fernandez, Carlos H. Miller, Lisa J. and Sadowski, Cheryl A. 2010. Considerations in the Treatment of Geriatric Depression. Research in Gerontological Nursing, Vol. 3, Issue. 3, p. 176.
Kuloglu, M. Ekinci, O. and Caykoylu, A. 2010. Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone. Journal of Psychopharmacology, Vol. 24, Issue. 4, p. 627.
Girardi, Paolo Pompili, Maurizio Innamorati, Marco Mancini, Michele Serafini, Gianluca Mazzarini, Lorenzo Del Casale, Antonio Tatarelli, Roberto and Baldessarini, Ross J. 2009. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Human Psychopharmacology: Clinical and Experimental, Vol. 24, Issue. 3, p. 177.
Mainguy, Yves 2009. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Human Psychopharmacology: Clinical and Experimental, Vol. 24, Issue. S1, p. S19.
Berrocoso, Esther and Mico, Juan A. 2009. Role of serotonin 5-HT1A receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice. The International Journal of Neuropsychopharmacology, Vol. 12, Issue. 01, p. 61.
Takahashi, Hitoshi and Ishigooka, Jun 2009. Improvement of Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction Without Worsening of Depressive Symptom After Switching to Milnacipran. Clinical Neuropharmacology, Vol. 32, Issue. 3, p. 177.
Boomershine, Chad S. and Crofford, Leslie J. 2009. A symptom-based approach to pharmacologic management of fibromyalgia. Nature Reviews Rheumatology, Vol. 5, Issue. 4, p. 191.
Riley, Andrea A. McEntee, Mindy L. Gerson, Linda and Dennison, Cheryl R. 2009. Depression as a Comorbidity to Diabetes: Implications for Management. The Journal for Nurse Practitioners, Vol. 5, Issue. 7, p. 523.
Dago, Pedro Luis 2009. Factors That Impact Choice of Antidepressant Treatment in Medically Complex Patients. CNS Spectrums, Vol. 14, Issue. S12, p. 20.
Ginsberg, Lawrence D. 2009. Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder. CNS Spectrums, Vol. 14, Issue. S12, p. 8.
Pandi-Perumal, Seithikurippu R. Trakht, Ilya Srinivasan, Venkataramanujan Spence, D. Warren Poeggeler, Burkhard Hardeland, Ruediger and Cardinali, Daniel P. 2009. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. The World Journal of Biological Psychiatry, Vol. 10, Issue. 4-2, p. 342.
Hewett, K Chrzanowski, W Schmitz, M Savela, A Milanova, V Gee, M Krishen, A Millen, L Leary, MO and Modell, J 2009. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Journal of Psychopharmacology, Vol. 23, Issue. 5, p. 531.
Zinck, Suzanne Bagnell, Alexa Bond, Kenneth and Newton, Amanda S. 2009. The Cochrane library and the treatment of major depression in children and youth: an overview of reviews. Evidence-Based Child Health: A Cochrane Review Journal, Vol. 4, Issue. 4, p. 1336.
Tsutsui-Kimura, Iku Ohmura, Yu Izumi, Takeshi Yamaguchi, Taku Yoshida, Takayuki and Yoshioka, Mitsuhiro 2009. The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats. Behavioural Pharmacology, Vol. 20, Issue. 5-6, p. 474.
Zimmerman, Mark 2009. Introduction: Selecting an Antidepressant. CNS Spectrums, Vol. 14, Issue. S12, p. 4.
Suenaga, Eunice Mayumi Ifa, Demian R. Cruz, Alessandro Carvalho Pereira, Renata Abib, Eduardo Tominga, Mineko and Nakaie, Clovis Ryuichi 2009. Automated determination of venlafaxine in human plasma by on-line SPE-LC-MS/MS. Application to a bioequivalence study. Journal of Separation Science, Vol. 32, Issue. 4, p. 637.
Miller, Laura J Girgis, Christina and Gupta, Renu 2009. Depression and Related Disorders during the Female Reproductive Cycle. Women's Health, Vol. 5, Issue. 5, p. 577.
Galletti, Francesca Cupini, Letizia Maria Corbelli, Ilenia Calabresi, Paolo and Sarchielli, Paola 2009. Pathophysiological basis of migraine prophylaxis. Progress in Neurobiology, Vol. 89, Issue. 2, p. 176.
Castagné, Vincent Porsolt, Roger D. and Moser, Paul 2009. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. European Journal of Pharmacology, Vol. 616, Issue. 1-3, p. 128.
Kennedy, Sidney H. and Rizvi, Sakina 2009. Sexual Dysfunction, Depression, and the Impact of Antidepressants. Journal of Clinical Psychopharmacology, Vol. 29, Issue. 2, p. 157.
Stahl, Stephen M. 2009. Fibromyalgia-pathways and neurotransmitters. Human Psychopharmacology: Clinical and Experimental, Vol. 24, Issue. S1, p. S11.
Bennett, Robert M. 2009. A new treatment option for fibromyalgia. Nature Reviews Rheumatology, Vol. 5, Issue. 4, p. 188.
Mease, Philip J. 2009. Further Strategies for Treating Fibromyalgia: The Role of Serotonin and Norepinephrine Reuptake Inhibitors. The American Journal of Medicine, Vol. 122, Issue. 12, p. S44.
Leo, Raphael J 2009. Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia. International Journal of Clinical Rheumatology, Vol. 4, Issue. 5, p. 507.
Krystal, John H. and Neumeister, Alexander 2009. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Research, Vol. 1293, p. 13.
Mantovani, M Dooley, DJ Weyerbrock, A Jackisch, R and Feuerstein, TJ 2009. Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes*. British Journal of Pharmacology, Vol. 158, Issue. 7, p. 1848.
Koga, M. Kodaka, F. Miyata, H. and Nakayama, K. 2009. Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. Acta Psychiatrica Scandinavica, Vol. 120, Issue. 4, p. 329.
Olié, J.-P. Gourion, D. Montagne, A. Rostin, M. and Poirier, M.-F. 2009. Milnacipran et venlafaxine à posologie flexible (jusqu’à 200 mg/j) dans le traitement ambulatoire des épisodes dépressifs majeurs modérés à sévères de l’adulte : étude exploratoire de 24 semaines, randomisée en double insu. L'Encéphale, Vol. 35, Issue. 6, p. 595.
Chang, Victor Gonzalez, Peter and Akuthota, Venu 2008. Evidence-informed management of chronic low back pain with adjunctive analgesics. The Spine Journal, Vol. 8, Issue. 1, p. 21.
Vorobeychik, Yakov and Acquadro, Martin A. 2008. Use of Atomoxetine in a Patient with Fibromyalgia Syndrome and Attention-Deficit Hyperactivity Disorder. Journal of Musculoskeletal Pain, Vol. 16, Issue. 3, p. 189.
Hsiao, Mei-Chun and Liu, Chia-Yih 2008. Successful duloxetine use to prevent venlafaxine withdrawal symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, Issue. 2, p. 576.
McCleane, Gary 2008. Antidepressants as Analgesics. CNS Drugs, Vol. 22, Issue. 2, p. 139.
Rahman, Zia Ring, Robert H. Young, Kimberly Platt, Brian Lin, Qian Schechter, Lee E. Rosenzweig-Lipson, Sharon and Beyer, Chad E. 2008. Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine. Brain Research, Vol. 1203, p. 68.
Baastrup, Cathrine and Finnerup, Nanna B 2008. Pharmacological Management of Neuropathic Pain Following Spinal Cord Injury. CNS Drugs, Vol. 22, Issue. 6, p. 455.
Kamath, Jayesh and Handratta, Venkatesh 2008. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Review of Neurotherapeutics, Vol. 8, Issue. 12, p. 1787.
Yoshida, Keizo Higuchi, Hisashi Takahashi, Hitoshi Kamata, Mitsuhiro Sato, Kazuhiro Inoue, Kazuyuki Suzuki, Toshio Itoh, Kunihiko and Ozaki, Norio 2008. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Human Psychopharmacology: Clinical and Experimental, Vol. 23, Issue. 2, p. 121.
Perahia, David G.S. Pritchett, Yili Lu Kajdasz, Daniel K. Bauer, Michael Jain, Rakesh Russell, James M. Walker, Daniel J. Spencer, Kimberly A. Froud, Debbie M. Raskin, Joel and Thase, Michael E. 2008. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of Psychiatric Research, Vol. 42, Issue. 1, p. 22.
Kasper, Siegfried 2008. Everyday Problems in Treating Depression: Focus on SNRIs. CNS Spectrums, Vol. 13, Issue. S11, p. 4.
Begré, Stefan Traber, Martin Gerber, Martin and von Känel, Roland 2008. Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: An observational study in primary care. European Psychiatry, Vol. 23, Issue. 3, p. 178.
Baldwin, David Moreno, Ricardo A. and Briley, Mike 2008. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology: Clinical and Experimental, Vol. 23, Issue. 6, p. 527.
Trivedi, Madhukar H. Desaiah, Durisala Ossanna, Melissa J. Pritchett, Yili L. Brannan, Stephen K. and Detke, Michael J. 2008. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. International Clinical Psychopharmacology, Vol. 23, Issue. 3, p. 161.
Montgomery, Stuart A. 2008. The under-recognized role of dopamine in the treatment of major depressive disorder. International Clinical Psychopharmacology, Vol. 23, Issue. 2, p. 63.
Mago, Rajnish Mahajan, Rajeev and Thase, Michael E. 2008. Medically serious adverse effects of newer antidepressants. Current Psychiatry Reports, Vol. 10, Issue. 3, p. 249.
Lawson, Kim 2008. Pharmacological treatments of fibromyalgia: Do complex conditions need complex therapies?. Drug Discovery Today, Vol. 13, Issue. 7-8, p. 333.
Chen, Chen Dyck, Brian Fleck, Beth A. Foster, Alan C. Grey, Jonathan Jovic, Florence Mesleh, Michael Phan, Kasey Tamiya, Junko Vickers, Troy and Zhang, Mingzhu 2008. Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorganic & Medicinal Chemistry Letters, Vol. 18, Issue. 4, p. 1346.
Singh, Gursharanjit Ghosh, Bijaya Kaushalkumar, Dave and Somsekhar, Vanita 2008. Screening of Venlafaxine Hydrochloride for Transdermal Delivery: Passive Diffusion and Iontophoresis. AAPS PharmSciTech, Vol. 9, Issue. 3, p. 791.
Lennestål, Roland and Källén, Bengt 2007. Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants. Journal of Clinical Psychopharmacology, Vol. 27, Issue. 6, p. 607.
Millan, Mark J. and Dekeyne, Anne 2007. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with α/β-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors. The International Journal of Neuropsychopharmacology, Vol. 10, Issue. 05,
Nash, Jon and Nutt, David 2007. Psychopharmacology of anxiety. Psychiatry, Vol. 6, Issue. 4, p. 143.
Walter, Uwe Prudente-Morrissey, Lara Herpertz, Sabine C. Benecke, Reiner and Hoeppner, Jacqueline 2007. Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Research: Neuroimaging, Vol. 155, Issue. 1, p. 67.
Zhang, Lu Chappell, Jill Gonzales, Celedon R Small, David Knadler, Mary P Callaghan, JT Francis, Jennie L Desaiah, Durisala Leibowitz, Mark Ereshefsky, Larry Hoelscher, David Leese, Philip T and Derby, Michael 2007. QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study. Journal of Cardiovascular Pharmacology, Vol. 49, Issue. 3, p. 146.
Millet, B. 2007. Apport des ISRS et IRSNA dans l’anxiodépression. L'Encéphale, Vol. 33, Issue. 4, p. 699.
Kako, Yuki Niwa, Yusuke Toyomaki, Atsuhito Yamanaka, Hiroyoshi Kitagawa, Nobuki Denda, Kenzo and Koyama, Tsukasa 2007. A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran. Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, Issue. 3, p. 772.
Bradesi, Sylvie and Mayer, Emeran A 2007. Novel therapeutic approaches in IBS. Current Opinion in Pharmacology, Vol. 7, Issue. 6, p. 598.
Hartford, James Kornstein, Susan Liebowitz, Michael Pigott, Teresa Russell, James Detke, Michael Walker, Daniel Ball, Susan Dunayevich, Eduardo Dinkel, Jeff and Erickson, Janelle 2007. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology, Vol. 22, Issue. 3, p. 167.
Rosenzweig-Lipson, Sharon Beyer, Chad E. Hughes, Zoë A. Khawaja, Xavier Rajarao, Somana J. Malberg, Jessica E. Rahman, Zia Ring, Robert H. and Schechter, Lee E. 2007. Differentiating antidepressants of the future: Efficacy and safety. Pharmacology & Therapeutics, Vol. 113, Issue. 1, p. 134.
Wernicke, Joachim Lled??, Alberto Raskin, Joel Kajdasz, Daniel K and Wang, Fujun 2007. An Evaluation of the Cardiovascular Safety Profile of Duloxetine. Drug Safety, Vol. 30, Issue. 5, p. 437.
Kamath, Jayesh DeMartinis, Nicholas and Handratta, Venkatesh 2007. Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. Future Neurology, Vol. 2, Issue. 4, p. 361.
Stahl, Stephen M. Ahmed, Saeeduddin and Haudiquet, Vincent 2007. Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Long-Term Treatment with Venlafaxine ER. CNS Spectrums, Vol. 12, Issue. 09, p. 703.
Roggen, Heidi Kehler, Jan Stensbøl, Tine Bryan and Hansen, Tore 2007. Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. Bioorganic & Medicinal Chemistry Letters, Vol. 17, Issue. 10, p. 2834.
Higuchi, Teruhiko and Briley, Mike 2007. Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan. Neuropsychiatric Disease and Treatment, Vol. 3, Issue. 1, p. 41.
WILSON, A.D. HOWELL, C. and WARING, W.S. 2007. VENLAFAXINE INGESTION IS ASSOCIATED WITH RHABDOMYOLYSIS IN ADULTS: A CASE SERIES. The Journal of Toxicological Sciences, Vol. 32, Issue. 1, p. 97.
March, John S. Entusah, A. Richard Rynn, Moira Albano, Anne Marie and Tourian, Karen A. 2007. A Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder. Biological Psychiatry, Vol. 62, Issue. 10, p. 1149.
Barbier, Ann J. Aluisio, Leah Lord, Brian Qu, Ying Wilson, Sandy J. Boggs, Jamin D. Bonaventure, Pascal Miller, Kirsten Fraser, Ian Dvorak, Lisa Pudiak, Cindy Dugovic, Christine Shelton, Jonathan Mazur, Curt Letavic, Michael A. Carruthers, Nicholas I. and Lovenberg, Timothy W. 2007. Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor. European Journal of Pharmacology, Vol. 576, Issue. 1-3, p. 43.
Bergman, Stefan 2007. Management of musculoskeletal pain. Best Practice & Research Clinical Rheumatology, Vol. 21, Issue. 1, p. 153.
Chen, Zhengming and Skolnick, Phil 2007. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, Vol. 16, Issue. 9, p. 1365.
Lang, Undine E. Stogowski, Dariusz Schulze, Doreen Domula, Markus Schmidt, Eckart GaLLinat, Jüergen Tugtekin, Sems Malte and FeLber, Werner 2007. Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. Journal of Psychopharmacology, Vol. 21, Issue. 5, p. 553.
Perdrizet-Chevallier, Catherine 2007. Troubles sexuels au cours des traitements antidépresseurs lors de leur utilisation dans les cancers gynécologiques. Psycho-Oncologie, Vol. 1, Issue. 4, p. 279.
Saitoh, Akiyoshi Yamaguchi, Kazumasa Tatsumi, Yoshimi Murasawa, Hiroyasu Nakatani, Akiko Hirose, Noritaka Yamada, Misa Yamada, Mitsuhiko and Kamei, Junzo 2007. Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. Psychopharmacology, Vol. 191, Issue. 4, p. 857.
Montgomery, Stuart 2006. Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development. International Journal of Psychiatry in Clinical Practice, Vol. 10, Issue. sup2, p. 5.
King, Tamara Rao, Srinivas Vanderah, Todd Chen, Qingmin Vardanyan, Anna and Porreca, Frank 2006. Differential Blockade of Nerve Injury–Induced Shift in Weight Bearing and Thermal and Tactile Hypersensitivity by Milnacipran. The Journal of Pain, Vol. 7, Issue. 7, p. 513.
Kim, H. Florence and Fisch, Michael J. 2006. Antidepressant use in ambulatory cancer patients. Current Oncology Reports, Vol. 8, Issue. 4, p. 275.
McAllister-Williams, R Hamish 2006. Duloxetine in the management of depression. Future Neurology, Vol. 1, Issue. 6, p. 713.
Pakalapati, Ravi K Bolisetty, Srinivas Austin, Marie-Paule and Oei, Julee 2006. Neonatal seizures from in utero venlafaxine exposure. Journal of Paediatrics and Child Health, Vol. 42, Issue. 11, p. 737.
Schwartz, Thomas L and Nihalani, Nikhil 2006. Tiagabine in anxiety disorders. Expert Opinion on Pharmacotherapy, Vol. 7, Issue. 14, p. 1977.
Baghai, Thomas C. Volz, Hans-Peter and Möller, Hans-Jürgen 2006. Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. The World Journal of Biological Psychiatry, Vol. 7, Issue. 4, p. 198.
Thase, Michael E. Clayton, Anita H. Haight, Barbara R. Thompson, April H. Modell, Jack G. and Johnston, J. Andrew 2006. A Double-blind Comparison Between Bupropion XL and Venlafaxine XR. Journal of Clinical Psychopharmacology, Vol. 26, Issue. 5, p. 482.
Ramadan, Nabih M. and Buchanan, Thomas M. 2006. New and future migraine therapy. Pharmacology & Therapeutics, Vol. 112, Issue. 1, p. 199.
The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of both serotonin (5-HT) and norepinephrine with differing selectivity. Whereas milnacipran blocks 5-HT and norepinephrine reuptake with equal affinity, duloxetine has a 10-fold selectivity for 5-HT and venlafaxine a 30-fold selectivity for 5-HT. All three SNRIs are efficacious in treating a variety of anxiety disorders. There is no evidence for major differences between SNRIs and SSRIs in their efficacy in treating anxiety disorders. In contrast to SSRIs, which are generally ineffective in treating chronic pain, all three SNRIs seem to be helpful in relieving chronic pain associated with and independent of depression. Tolerability of an SNRI at therapeutic doses varies within the class. Although no direct comparative data are available, venlafaxine seems to be the least well-tolerated, combining serotonergic adverse effects (nausea, sexual dysfunction, withdrawal problems) with a dose-dependent cardiovascular phenomenon, principally hypertension. Duloxetine and milnacipran appear better tolerated and essentially devoid of cardiovascular toxicity.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between September 2016 - 24th March 2018. This data will be updated every 24 hours.